Active Surveillance and Safety/Efficacy Evaluation of Innovative Devices for Structural Heart Disease Intervention (ASSEE-SHD)
Establishment of Active Surveillance and Safety and Efficacy Evaluation Indicators for Innovative Devices Used in Interventional Treatment of Structural Heart Disease
This study aims to establish an active surveillance system to evaluate the safety and effectiveness of innovative medical devices used in the interventional treatment of structural heart disease. The devices of interest include a biodegradable patent foramen ovale (PFO) closure device and a transcatheter mitral valve edge-to-edge repair system. Clinical information from patients receiving these devices during routine clinical care will be collected and analyzed. The findings will help evaluate the safety and effectiveness of these devices and support the development of appropriate clinical evaluation indicators and long-term monitoring strategies.
Studieoversigt
Status
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Xinyi Xu
- Telefonnummer: +86 18930830756
- E-mail: 3342@scmc.com.cn
Undersøgelse Kontakt Backup
- Navn: Kai Wang
- Telefonnummer: +86 15317921903
- E-mail: 30192@scmc.com.cn
Studiesteder
-
-
-
Beijing, Kina
- Ikke rekrutterer endnu
- Beijing Anzhen Hospital, Capital Medical University
-
Kontakt:
- Yizhen Yang
- Telefonnummer: +86 13261985610
- E-mail: yangyizhen2005@126.com
-
Ledende efterforsker:
- Wenhui Wu
-
Beijing, Kina
- Ikke rekrutterer endnu
- FUWAI Hospital, CAMS&PUMC
-
Kontakt:
- Jing Dong
- Telefonnummer: +86 15810174302
- E-mail: Djing0324@163.com
-
Ledende efterforsker:
- Guangzhi Zhao
-
Shanghai, Kina
- Ikke rekrutterer endnu
- East Hospital, Tongji University
-
Kontakt:
- Ying Hao
- Telefonnummer: +86 18049898248
- E-mail: supergreathy@163.com
-
Ledende efterforsker:
- Linxiang Lu
-
-
Gansu
-
Lanzhou, Gansu, Kina
- Rekruttering
- The First Hospital of Lanzhou University
-
Kontakt:
- Sixiong Hu
- Telefonnummer: +86 17693433056
- E-mail: hsx1120587348@126.com
-
Ledende efterforsker:
- Jizhe Xu
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- Ikke rekrutterer endnu
- Guangdong Provincial People's Hospital
-
Kontakt:
- Xiaotong Wen
- Telefonnummer: +86 18123548072
- E-mail: 1127337995@qq.com
-
Ledende efterforsker:
- Caojin Zhang
-
-
Henan
-
Zhengzhou, Henan, Kina
- Rekruttering
- Fuwai Central China Cardiovascular Hospital
-
Kontakt:
- Menghao Li
- Telefonnummer: +86 18790660032
- E-mail: edward564@163.com
-
Ledende efterforsker:
- Shubo Song
-
-
Hubei
-
Wuhan, Hubei, Kina
- Rekruttering
- Zhongnan Hospital of Wuhan University
-
Kontakt:
- Lei Wang
- Telefonnummer: +86 18702797617
- E-mail: 119559295@qq.com
-
Ledende efterforsker:
- Gangcheng Zhang
-
-
Liaoning
-
Shenyang, Liaoning, Kina
- Ikke rekrutterer endnu
- General Hospital of Northern Theater Command, Chinese People's Liberation Army
-
Ledende efterforsker:
- Qiguang Wang
-
Kontakt:
- Jiawang Xiao
- Telefonnummer: +86 17790991821
- E-mail: xjw492918837@126.com
-
-
Shandong
-
Jinan, Shandong, Kina
- Ikke rekrutterer endnu
- Shandong Provincial Hospital
-
Kontakt:
- mingliang Dong
- Telefonnummer: +86 13573157896
- E-mail: dongmingliang2008@126.com
-
Ledende efterforsker:
- Anbiao Wang
-
-
Sichuan
-
Chengdu, Sichuan, Kina
- Ikke rekrutterer endnu
- Sichuan Provincial People's Hospital
-
Kontakt:
- Xuechun Sun
- Telefonnummer: +86 18981838108
- E-mail: sunxchun@163.com
-
Ledende efterforsker:
- Yunshan Cao
-
-
Yunnan
-
Kunming, Yunnan, Kina
- Ikke rekrutterer endnu
- Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences/Affiliated Cardiovascular Hospital of Kunming Medical University
-
Ledende efterforsker:
- Cheng Wang
-
Kontakt:
- Kairui Yang
- Telefonnummer: +86 13987313055
- E-mail: 416719379@qq.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
- Biodegradable PFO Closure Device Cohort: Patients with confirmed PFO-associated ischemic stroke who undergo implantation of a biodegradable PFO closure device.
- Transcatheter Mitral Valve Edge-to-Edge Repair (TEER) Cohort: Patients with functional or degenerative mitral regurgitation who undergo transcatheter mitral valve edge-to-edge repair using a TEER system.
Beskrivelse
Inclusion Criteria:
- Patients undergoing implantation of a biodegradable PFO closure device.
- Patients undergoing transcatheter mitral valve edge-to-edge repair.
Exclusion Criteria:
The participant expresses a desire to withdraw from the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Biodegradable Patent Foramen Ovale Closure Device
Participants with patent foramen ovale (PFO) who receive a biodegradable PFO closure device as part of routine clinical care will be included in this cohort. Clinical data will be collected to evaluate the safety and effectiveness of the device during follow-up. |
|
Transcatheter Mitral Valve Edge-to-Edge Repair System Cohort
Participants with degenerative or functional mitral regurgitation who undergo transcatheter mitral valve edge-to-edge repair using a transcatheter mitral valve edge-to-edge repair system. Safety and effectiveness outcomes will be assessed during follow-up. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Major Adverse Events
Tidsramme: At 1, 6, and 12 months after the procedure
|
Incidence of major adverse events related to the biodegradable PFO closure or transcatheter mitral valve edge-to-edge repair procedure during follow-up. |
At 1, 6, and 12 months after the procedure
|
|
Anatomical success of PFO closure within 12 months after biodegradable PFO occluder implantation, assessed by transthoracic echocardiography
Tidsramme: At 1, 6, and 12 months after the procedure
|
The proportion of participants achieving successful anatomical closure of the patent foramen ovale (PFO) during the 12-month follow-up period after biodegradable PFO occluder implantation, assessed by transthoracic echocardiography. |
At 1, 6, and 12 months after the procedure
|
|
Incidence of the composite clinical outcome of heart failure hospitalization, all-cause mortality, or cardiovascular mortality within 12 months after transcatheter edge-to-edge mitral valve repair
Tidsramme: At 1, 6, and 12 months after the procedure
|
The proportion of participants experiencing at least one of the following events during the 12-month follow-up period after TEER: hospitalization for heart failure, all-cause death, or cardiovascular death. Events will be assessed through clinical follow-up and review of medical records. |
At 1, 6, and 12 months after the procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Degree of device degradation
Tidsramme: At 1, 6, and 12 months after the procedure
|
The degree of degradation of the biodegradable PFO closure device will be assessed by echocardiography during follow-up. |
At 1, 6, and 12 months after the procedure
|
|
Incidence of residual shunt after PFO closure
Tidsramme: At 1, 6, and 12 months after the procedure.
|
The presence of residual shunt after implantation of the biodegradable PFO closure device will be assessed by echocardiography with contrast study, when applicable. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of re-intervention after PFO closure
Tidsramme: At 1, 6, and 12 months after the procedure.
|
The percentage of participants requiring reapeat intervention or surgical treatment related to the PFO closure device during follow-up. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of recurrent stroke after PFO closure
Tidsramme: At 1, 6, and 12 months after the procedure.
|
The occurrence of recurrent ischemic or hemorrhagic stroke during the follow-up period will be assessed by clinical evaluation and review of medical records. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of device-related thrombosis after PFO closure
Tidsramme: At 1, 6, and 12 months after the procedure.
|
The occurrence of thrombosis related to the biodegradable PFO closure device during follow-up will be assessed by echocardiography and clinical assessment. |
At 1, 6, and 12 months after the procedure.
|
|
Proportion of participants who underwent TEER and achieved immediate procedural success
Tidsramme: Within 24 hours after the procedure.
|
Immediate procedural success is defined as successful completion of the transcatheter mitral valve edge-to-edge repair procedure with post-procedural mitral regurgitation (MR) grade ≤2+, as assessed by echocardiography. |
Within 24 hours after the procedure.
|
|
Incidence of subsequent open-heart surgery in the TEER group
Tidsramme: At 1, 6, and 12 months after the procedure.
|
The number of participants undergoing subsequent open-heart surgery related to TEER during follow-up. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of ischemic or hemorrhagic stroke in the TEER group
Tidsramme: At 1, 6, and 12 months after the procedure.
|
The occurrence of ischemic or hemorrhagic stroke during follow-up in the TEER group will be assessed by clinical evaluation and review of medical records. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of bleeding events in the TEER group
Tidsramme: At 1, 6, and 12 months after the procedure.
|
The occurrence of bleeding events during follow-up in the TEER group will be assessed by clinical evaluation and review of medical records. |
At 1, 6, and 12 months after the procedure.
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Lijun Fu, Shanghai Children's Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- SCMC2024ZD0527503
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant-level data relevant to the study objectives, including baseline characteristics, procedural data, safety and efficacy outcomes, and follow-up data, will be shared.
IPD-delingstidsramme
Start Date: 12 months after publication of the primary results End Date: No end date
IPD-delingsadgangskriterier
De-identified individual participant-level data and supporting information will be available to qualified researchers upon reasonable request and subject to review and approval by the study investigators. Access will be provided for scientifically justified research purposes in accordance with applicable regulations and data protection requirements. Requests should be submitted to the study investigators, and approved data will be shared through a secure data transfer mechanism.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .